We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.
- Authors
Fasching, Peter A; Heusinger, Katharina; Haeberle, Lothar; Niklos, Melitta; Hein, Alexander; Bayer, Christian M; Rauh, Claudia; Schulz-Wendtland, Ruediger; Bani, Mayada R; Schrauder, Michael; Kahmann, Laura; Lux, Michael P; Strehl, Johanna D; Hartmann, Arndt; Dimmler, Arno; Beckmann, Matthias W; Wachter, David L
- Abstract
The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate marker for a favorable prognosis in breast cancer patients. Factors capable of predicting a pCR, such as the proliferation marker Ki67, may therefore help improve our understanding of the drug response and its effect on the prognosis. This study investigated the predictive and prognostic value of Ki67 in patients with invasive breast cancer receiving neoadjuvant treatment for breast cancer.
- Publication
BMC cancer, 2011, Vol 11, p486
- ISSN
1471-2407
- Publication type
Journal Article
- DOI
10.1186/1471-2407-11-486